Jyotika Rajawat

About

Jyotika Rajawat is a faculty at IAMGID, ONGC-CAS, University of Lucknow. She is working on Cancer biology to identify the mechanism of PARP and PARP inhibitors in therapeutics. Her research focuses on drug discovery and development. Dr. Rajawat has expertise in molecular biology, proteomics, and transcriptomics. She has a rich experience of 12 years in cancer research and teaching. Dr. Rajawat has written several peer-reviewed research articles, book chapters, newspaper articles, and has served as a reviewer for various international publishers.

Employment

• University of Lucknow Assistant Professor
  2022 - Present
• University of Lucknow Project Scientist
  2019 - 2022
• Central Drug Research Institute Project Scientist
  2015 - 2018
• National Centre For Cell Science Project Scientist
  2013 - 2015
• CHUQ Laval University Postdoctoral fellow
• University of Kota Lecturer

Education

• DAVV Indore MSc
• MS University of Baroda PhD

Projects & Funding

Projects & funding information is unavailable.

Publications (22)

• PARP1 inhibition regulates tumor progression through modulation of RhoGDIα and vimentin in triple negative breast cancer
  2026 DOI: 10.64898/2026.07.18.739208
  +Save
• PARP1 genetic variants modulate gene expression and cervical cancer susceptibility in a North Indian case-control study
  Molecular Biology Reports 2026 DOI: 10.1007/s11033-026-12655-4
  +Save
• Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer
  Biochemical and Biophysical Research Communications 2024 DOI: 10.1016/j.bbrc.2024.150943
  +Save
• A Review on Therapeutic Potential of Indian Herbal Plants to Counter Viral Infection and Disease Pathogenesis
  Current Traditional Medicine 2023 DOI: 10.2174/2215083808666220915121803
  +Save
• EPIDEMIOLOGICAL PROFILE AND ASSOCIATION OF VARYING HABITS WITH PRECANCER AND OSCC IN POPULATION OF NORTH INDIA
  International Journal of Pharmacy and Pharmaceutical Sciences 2023 DOI: 10.22159/ijpps.2023v15i2.46725
  +Save
• Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.
  Medical oncology (Northwood, London, England) 2022 DOI: 10.1007/s12032-022-01701-3
  +Save
• Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
  Current Drug Targets 2021 DOI: 10.2174/1389450122666210120142746
  +Save
• Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor
  Journal of Biomolecular Structure and Dynamics 2021 DOI: 10.1080/07391102.2021.1913229
  +Save
• Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
  International Journal of Molecular Sciences 2021 DOI: 10.3390/ijms22073553
  +Save
• Signaling interplay between PARP1 and ROS regulates stress-induced cell death and developmental changes in Dictyostelium discoideum.
  Experimental cell research 2020 DOI: 10.1016/j.yexcr.2020.112364
  +Save